Lexicon Pharmaceuticals To Host 2013 Research And Development Day
Thursday December 5, The Yale Club, 50 Vanderbilt Ave., New York, NY
To attend in person please RSVP to firstname.lastname@example.org
Live webcast also available through www.lexpharma.com
THE WOODLANDS, Texas, Dec. 2, 2013
THE WOODLANDS, Texas, Dec. 2, 2013 /PRNewswire/ --Lexicon Pharmaceuticals,
Inc. (Nasdaq: LXRX) will hold its R&D Day on Thursday, December 5, 2013 from
9:00 a.m. to 12:00 p.m. Eastern Time at the Yale Club, 50 Vanderbilt Ave., in
New York City. Members of Lexicon's senior management team will provide
in-depth reviews of the company's drugdevelopment programs. The agenda will
include a presentation by guest speaker Jake Kushner, M.D., Section Head,
Pediatric Diabetes and Endocrinology, Baylor College of Medicine, titled "Type
1 Diabetes, a Clinical Area of Tremendous Unmet Need".
To attend in person, please RSVP to email@example.com or 281-863-3264.
A live webcast of the event may be accessed on Lexicon's corporate website at
www.lexpharma.com. An archived version of the webcast will be available
for10 days after the event on the company's website.
Lexicon is a biopharmaceutical company focused on discovering breakthrough
treatments for human disease. Lexicon currently has multiple programs in
clinical development for diabetes, irritable bowel syndrome, carcinoid
syndrome and other indications, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has focused drug
discovery efforts on these biologically-validated targets to create its
extensive pipeline of clinical and preclinical programs. For additional
information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual property, as
well as other matters that are not historical facts or information. All
forward-looking statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to successfully
conduct preclinical and clinical development of its potential drug candidates,
advance additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial value of its
drug candidates, that may cause Lexicon's actual results to be materially
different from any future results expressed or implied by such forward-looking
statements. Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year ended
December 31, 2012, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such forward-looking
statements, whether as a result of new information, future events or
SOURCE Lexicon Pharmaceuticals, Inc.
Contact: Alex Abuin, Ph.D., Vice President, Communications and Alliance
Management, Lexicon, 281/863-3213, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.